Author/Authors :
Michel Anoumou Missinou، نويسنده , , Steffen Borrmann، نويسنده , , Andreas Schindler، نويسنده , , Saadou Issifou، نويسنده , , Ayola A Adegnika، نويسنده , , Pierre-Blaise Matsiegui، نويسنده , , Ronald Binder، نويسنده , , Bertrand Lell، نويسنده , , Jochen Wiesner، نويسنده , , Thomas Baranek، نويسنده , , Hassan Jomaa، نويسنده , , Peter G Kremsner، نويسنده ,
Abstract :
Safe and effective antimalarial drugs with new methods of action are urgently needed. Fosmidomycin inhibits the synthesis of isoprenoid by Plasmodium falciparum, and suppresses the growth of multidrug-resistant strains in vitro. Our aim was to assess the efficacy and tolerability of fosmidomycin in adults with malaria in Gabon. We administered the drug for 5, 4, or 3 days (1–2 g every 8 h), in nine, eight, and ten evaluable patients, respectively. All treatment regimens were well tolerated. Cure rates by day 14 were 89% (eight of nine), 88% (seven of eight), and 60% (six of ten), for treatment durations of 5, 4, and 3 days, respectively. These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more.
